Kieburtz, Karl, McDermott, Michael P., Voss, Tiffini S., Corey-Bloom, Jody, Deuel, Lisa M., Dorsey, E. Ray, Factor, Stewart, Geschwind, Michael D., Hodgeman, Karen, Kayson, Elise, Noonberg, Sarah, Pourfar, Michael, Rabinowitz, Karen, Ravina, Bernard, Sanchez-Ramos, Juan, Seely, Lynn, Walker, Francis, Feigin, Andrew

Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]

Orrell, Martin, Yates, Lauren A., Burns, Alistair, Russell, Ian, Woods, Robert T, Hoare, Zoe, Moniz-Cook, Esme, Henderson, Catherine, Knapp, Martin, Spector, Aimee, Orgeta, Vasiliki

Background: Improving the quality of care for people with dementia and their carers has become a national priority in many countries. Cognitive Stimulation Therapy (CST) groups can be beneficial in improving cognition and quality of life for people with dementia. The aim of the current study is to develop and evaluate a home-based individual Cognitive […]

Burstein, Aaron H, Grimes, Imogene, Galasko, Douglas R, Aisen, Paul S, Sabbagh, Marwan, Mjalli, Adnan MM

Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]